Chapter review

Must know

• Pharmacokinetic Alterations: Fat and Water DistributionTotal body water decreases by 10% to 15% in older adults, while total body fat increases by 20% to 40%.

  • Total body water decreases by 10% to 15% in older adults, while total body fat increases by 20% to 40%.
  • Hydrophilic (water-soluble) psychotropics like lithium distribute into a smaller volume of distribution, producing higher peak serum concentrations and elevated toxicity risk at standard adult doses.
  • Lipophilic (fat-soluble) psychotropics like diazepam, chlordiazepoxide, and long-acting antipsychotics distribute into an expanded fat mass, significantly increasing their volume of distribution.
  • An increased volume of distribution for lipophilic drugs prolongs their elimination half-life, leading to drug accumulation, daytime somnolence, cognitive slowing, ataxia, and falls.
  • Serum albumin levels often decrease in frail older adults, reducing protein binding for highly bound drugs like valproate and increasing the active free drug concentration.
  • Always follow the clinical rule to start low and go slow, initiating lipophilic and hydrophilic psychotropics at 50% of the standard young adult starting dose while titrating to therapeutic targets.
• Renal Function: eGFR vs. Serum CreatinineSerum creatinine remains deceptively normal in older adults due to age-related loss of muscle mass, masking a renal function decline of up to 30 percent or more.

  • Serum creatinine remains deceptively normal in older adults due to age-related loss of muscle mass, masking a renal function decline of up to 30 percent or more.
  • eGFR (estimated glomerular filtration rate) is the gold standard metric for evaluating renal clearance and driving psychotropic dosing decisions in geriatric patients.
  • eGFR greater than 60 mL/min indicates adequate renal clearance where most psychotropics require no dosage adjustment.
  • eGFR less than 60 mL/min defines moderate renal impairment that requires dose reduction or drug switching for renally cleared psychotropics, including lithium, gabapentin, and paliperidone.
  • eGFR less than 30 mL/min represents severe renal impairment requiring significant dose decreases or complete avoidance of renally excreted psychotropics.
  • Lithium toxicity risk increases dramatically in older adults when renal clearance drops, requiring frequent lab monitoring of eGFR and serum drug levels.
• Dosing Thresholds by eGFR LeveleGFR greater than 60 mL/min: Standard psychotropic dosing is generally safe.

  • eGFR greater than 60 mL/min: Standard psychotropic dosing is generally safe.
  • eGFR 30 to 50 mL/min: Moderate clearance reduction. Reduce starting doses of renally cleared medications by 25 to 50 percent or select hepatically metabolized alternatives.
  • eGFR less than 30 mL/min: Severe clearance reduction. Avoid lithium if possible, or use extreme caution with reduced doses and frequent blood level monitoring.
• Serum CreatinineFast mental label: Deceptive muscle breakdown marker.

  • Fast mental label: Deceptive muscle breakdown marker.
  • Geriatric limitation: Normal values mask significant renal impairment due to low muscle mass.
  • Boards are testing: Why you should never rely on serum creatinine alone in older adults.
  • Fast mental label: True renal clearance metric.
  • Geriatric value: Accurately reflects functional nephron clearance regardless of muscle mass.
  • Boards are testing: The primary lab value used to adjust renally excreted psychotropics.
• Liver Metabolism: CYP450 Enzyme ChangesHepatic blood flow decreases by 20% to 50% in older adults, while overall liver mass decreases by 20% to 40%.

  • Hepatic blood flow decreases by 20% to 50% in older adults, while overall liver mass decreases by 20% to 40%.
  • Phase I metabolism involving CYP450 oxidation, reduction, and hydroxylation decreases significantly with age, prolonging drug elimination half-lives and raising toxicity risks.
  • Phase II metabolism involving glucuronidation, acetylation, and sulfation remains largely preserved in normal aging.
  • LOT benzodiazepines (lorazepam, oxazepam, temazepam) undergo Phase II glucuronidation directly and bypass Phase I CYP450 oxidation, making them preferred when benzodiazepine therapy is unavoidable.
  • CYP2D6 inhibition by fluoxetine and paroxetine blocks the breakdown of co-administered substrates like metoprolol, causing severe bradycardia, hypotension, and falls.
  • First-pass hepatic extraction is reduced in older adults, which increases the oral bioavailability and peak plasma concentrations of highly extracted psychotropics.
• Aging Liver PhysiologyHepatic mass: Decreases by 20% to 40% in older adults, reducing overall metabolic capacity.

  • Hepatic mass: Decreases by 20% to 40% in older adults, reducing overall metabolic capacity.
  • Hepatic blood flow: Decreases by 20% to 50%, reducing first-pass clearance and increasing systemic bioavailability.
  • Serum liver enzymes: AST, ALT, and alkaline phosphatase remain in normal ranges in healthy aging; elevations signal primary liver pathology rather than normal age-related changes.
• Phase I Metabolism (Oxidation)Mechanism: Utilizes CYP450 isoenzymes for oxidation, reduction, hydroxylation, and demethylation.

  • Mechanism: Utilizes CYP450 isoenzymes for oxidation, reduction, hydroxylation, and demethylation.
  • Aging effect: Significantly reduced due to decreases in liver mass, perfusion, and enzyme activity.
  • Clinical impact: Slower drug clearance, prolonged elimination half-life, and drug accumulation.
  • Affected drugs: diazepam, alprazolam, chlordiazepoxide, flurazepam, tertiary TCAs, and fluoxetine.
• Phase II Metabolism (Conjugation)Mechanism: Converts drugs into water-soluble metabolites via glucuronidation, acetylation, and sulfation.

  • Mechanism: Converts drugs into water-soluble metabolites via glucuronidation, acetylation, and sulfation.
  • Aging effect: Preserved and minimally altered by normal aging.
  • Clinical impact: Predictable clearance without significant accumulation.
  • Preferred drugs: lorazepam, oxazepam, and temazepam (the LOT benzodiazepines).
• SignpostsFor depression in older adults, choose SSRIs with minimal CYP450 inhibition such as sertraline or escitalopram (or citalopram with a maximum dose of 20 mg daily to avoid QTc prolongation). Avoid fluoxetine due to its long half-life and paroxetine due to anticholinergic effects an

  • fluoxetine and paroxetine are potent CYP2D6 inhibitors. Co-prescribing them with CYP2D6 substrates like metoprolol, carvedilol, or risperidone blocks substrate clearance, causing elevated drug levels, severe bradycardia, profound hypotension, and falls.
  • Long-acting benzodiazepines cleared by Phase I oxidation (diazepam, chlordiazepoxide) accumulate in geriatric adipose tissue, causing prolonged sedation, ataxia, confusion, and hip fractures.
  • Selecting diazepam or alprazolam for an elderly patient who requires short-term anxiolysis. Boards expect you to select lorazepam, oxazepam, or temazepam because they bypass Phase I oxidation.
  • Assuming normal AST and ALT levels indicate youthful hepatic drug clearance in an older adult. Liver enzymes measure acute cellular injury, not functional metabolic clearance rate.

  Board trap. Selecting diazepam or alprazolam for an elderly patient who requires short-term anxiolysis. Boards expect you to select lorazepam, oxazepam, or temazepam because they bypass Phase I oxidation.

  Safety. fluoxetine and paroxetine are potent CYP2D6 inhibitors. Co-prescribing them with CYP2D6 substrates like metoprolol, carvedilol, or risperidone blocks substrate clearance, causing elevated drug levels, severe bradycardia, profound hypotension, and falls.

• Phase I Oxidation vs Phase II ConjugationThink: Phase I decreases with age; Phase II is preserved.

  • Think: Phase I decreases with age; Phase II is preserved.
  • Priority: Choose Phase II cleared medications to prevent drug accumulation in older adults.
  • Boards are testing: Recognition that LOT benzodiazepines (lorazepam, oxazepam, temazepam) bypass age-related CYP450 oxidation decline.
  • Mini example: An 82-year-old patient needs short-term anxiolysis. Select lorazepam over diazepam because lorazepam undergoes Phase II glucuronidation.
  • Think: High CYP450 inhibition causes severe drug interactions; low CYP450 inhibition is safe in polypharmacy.
  • Priority: Avoid fluoxetine and paroxetine in older adults taking cardiac or psychotropic co-medications.
• Quick Answerlorazepam is the best choice because it undergoes Phase II glucuronidation, which remains intact in older adults.

  • lorazepam is the best choice because it undergoes Phase II glucuronidation, which remains intact in older adults.
• Key Cluelorazepam, along with oxazepam and temazepam, is cleared exclusively through Phase II hepatic glucuronidation. Phase II conjugation pathways are preserved in aging, preventing drug accumulation, excessive sedation, and ataxia.

  • lorazepam, along with oxazepam and temazepam, is cleared exclusively through Phase II hepatic glucuronidation. Phase II conjugation pathways are preserved in aging, preventing drug accumulation, excessive sedation, and ataxia.
  • A. diazepam undergoes Phase I CYP2C19 and CYP3A4 oxidation, generating active long-acting metabolites that accumulate and cause falls.
  • C. alprazolam requires Phase I CYP3A4 oxidation, which is impaired in older adults, leading to prolonged elimination half-life and toxicity.
  • D. chlordiazepoxide is a long-acting benzodiazepine cleared by Phase I oxidation that accumulates in geriatric fat tissue and carries a high risk of delirium.
• Active Recall Checkpoints1. What percentage decrease in hepatic blood flow and liver mass occurs in normal aging?

  • 1. What percentage decrease in hepatic blood flow and liver mass occurs in normal aging?
  • 2. Which liver metabolic pathway decreases significantly with age: Phase I oxidation or Phase II conjugation?
  • 3. What three benzodiazepines make up the LOT group that bypasses Phase I oxidation?
  • 4. Why does reduced first-pass hepatic extraction increase systemic drug exposure in older adults?
  • 5. Which two SSRIs are potent CYP2D6 inhibitors that should generally be avoided in geriatric polypharmacy?
• Practice Question: Best Lab for Renal AssessmenteGFR is the single most accurate lab metric for evaluating renal clearance in older adults.

  • eGFR is the single most accurate lab metric for evaluating renal clearance in older adults.
  • Serum creatinine alone is deceptive in elderly patients because age-related loss of muscle mass reduces creatinine production, masking up to a 30% reduction in renal filtration.
  • An eGFR greater than 60 mL/min indicates adequate renal clearance for standard psychotropic dosing.
  • An eGFR below 60 mL/min requires dosage reduction, extended dosing intervals, or selecting non-renally cleared alternatives.
  • Lithium is eliminated almost entirely unchanged by the kidneys, making baseline and routine eGFR monitoring essential.
  • Other renally cleared psychotropics requiring renal dose adjustments in aging include gabapentin, pregabalin, topiramate, and paliperidone.
• Serum Creatinine versus eGFReGFR: Estimated glomerular filtration rate incorporates age, sex, and serum creatinine to estimate actual renal clearance. It provides the true measure of functional nephron capacity.

  • eGFR: Estimated glomerular filtration rate incorporates age, sex, and serum creatinine to estimate actual renal clearance. It provides the true measure of functional nephron capacity.
• Clinical Signposts for BoardsEvaluate eGFR as the primary lab value when assessing renal function prior to initiating renally cleared psychotropics in older adults.

  • Evaluate eGFR as the primary lab value when assessing renal function prior to initiating renally cleared psychotropics in older adults.
  • Assuming normal renal function based solely on a normal serum creatinine level in an elderly patient. Test writers use normal serum creatinine values to trick candidates into prescribing full adult doses of renally cleared medications.
  • Imppaired renal clearance of lithium leads to drug accumulation and severe lithium toxicity. Watch for red-flag signs including coarse hand tremors, ataxia, dysarthria, confusion, and seizures.

  Board trap. Assuming normal renal function based solely on a normal serum creatinine level in an elderly patient. Test writers use normal serum creatinine values to trick candidates into prescribing full adult doses of renally cleared medications.

  Safety. Imppaired renal clearance of lithium leads to drug accumulation and severe lithium toxicity. Watch for red-flag signs including coarse hand tremors, ataxia, dysarthria, confusion, and seizures.

• Deprescribing Strategy: Low Hanging FruitDeprescribing low hanging fruit targets high-risk, low-benefit medications in patients age 65 and older, specifically benzodiazepines, sedative-hypnotics, and anticholinergics.

  • Deprescribing low hanging fruit targets high-risk, low-benefit medications in patients age 65 and older, specifically benzodiazepines, sedative-hypnotics, and anticholinergics.
  • Beers Criteria explicitly identifies strong anticholinergics such as diphenhydramine, hydroxyzine, and tertiary TCAs as high risk for inducing delirium, cognitive decline, constipation, and urinary retention.
  • eGFR below 60 mL/min requires renal dosage adjustments or drug switches for medications like lithium. Serum creatinine alone underestimates renal dysfunction due to age-related loss of muscle mass.
  • Antipsychotics carry an FDA Black Box Warning for increased mortality in elderly patients with dementia-related psychosis, primarily from cardiovascular events or infectious causes like pneumonia.
  • Polypharmacy, defined as taking 5 or more daily medications, significantly increases the risk of prescribing cascades, drug interactions, and fall-related fractures.
  • Deprescribing benzodiazepines requires a gradual dose reduction over weeks to months to prevent acute withdrawal symptoms, seizures, and severe rebound hyperarousal.
• Target Medication ClassesBenzodiazepines and Z-drugs (zolpidem, zaleplon, eszopiclone): High risk for motor impairment, ataxia, falls, fractures, delirium, and severe cognitive decline.

  • Benzodiazepines and Z-drugs (zolpidem, zaleplon, eszopiclone): High risk for motor impairment, ataxia, falls, fractures, delirium, and severe cognitive decline.
  • Anticholinergics (diphenhydramine, hydroxyzine, amitriptyline, benztropine, oxybutynin): High anticholinergic burden leading to acute confusion, memory disruption, dry mouth, constipation, and urinary retention.
  • Antipsychotics used for non-emergent behavioral management in dementia: Elevated mortality risk and metabolic or extrapyramidal adverse effects.
  • Duplicate Therapies: Co-prescribing multiple agents within the same drug class without clinical rationale.
• Priority Clinical RulesImplement non-pharmacological sleep hygiene or behavioral interventions before initiating any psychotropic medication in older adults.

  • Implement non-pharmacological sleep hygiene or behavioral interventions before initiating any psychotropic medication in older adults.
  • Antipsychotic administration in elderly patients with dementia-related psychosis carries an FDA Black Box Warning for increased mortality.
  • Anticholinergic toxicity can mimic worsening dementia or acute delirium. Always audit the medication list for OTC anticholinergics before ordering new psychiatric workups.
  • Relying solely on serum creatinine to assess renal function in an elderly patient. Reduced muscle mass keeps serum creatinine deceptively low despite significant renal impairment. Always utilize eGFR or calculated creatinine clearance.

  Board trap. Relying solely on serum creatinine to assess renal function in an elderly patient. Reduced muscle mass keeps serum creatinine deceptively low despite significant renal impairment. Always utilize eGFR or calculated creatinine clearance.

  Safety. Antipsychotic administration in elderly patients with dementia-related psychosis carries an FDA Black Box Warning for increased mortality.

• Benzodiazepines vs SSRIs in Older AdultsThink Benzodiazepines: High-risk low hanging fruit that causes ataxia, cognitive impairment, dependence, and fall fractures. Avoid for insomnia and chronic anxiety in older adults.

  • Think Benzodiazepines: High-risk low hanging fruit that causes ataxia, cognitive impairment, dependence, and fall fractures. Avoid for insomnia and chronic anxiety in older adults.
  • Think SSRIs: Preferred first-line agents for anxiety or depression in older adults (sertraline, escitalopram). Monitor for hyponatremia and SIADH.
  • Priority: Discontinue or taper benzodiazepines while initiating safer non-anticholinergic agents if chronic treatment is indicated.
• Serum Creatinine vs eGFR in Geriatric DosingThink Serum Creatinine: Inaccurate standalone indicator of renal function in older adults due to decreased muscle mass masking renal decline.

  • Think Serum Creatinine: Inaccurate standalone indicator of renal function in older adults due to decreased muscle mass masking renal decline.
  • Think eGFR: The gold standard metric for assessing geriatric renal clearance.
  • Priority: Adjust doses or switch renally cleared psychotropics when eGFR falls below 60 mL/min.
• Anticholinergic Delirium vs Primary Neurocognitive DisorderThink Anticholinergic Delirium: Acute onset of confusion, disorientation, dry mucous membranes, and urinary retention following medication changes or OTC antihistamine use.

  • Think Anticholinergic Delirium: Acute onset of confusion, disorientation, dry mucous membranes, and urinary retention following medication changes or OTC antihistamine use.
  • Think Primary Neurocognitive Disorder: Gradual, progressive decline in cognitive domains over months to years without acute physiological toxidrome features.
  • Priority: Deprescribe the offending anticholinergic agent immediately before diagnosing primary cognitive decline.
• Non-Pharmacological First-Line OptionsOlder adults account for 20% of the total scored items (27 out of 135 items) on the AANP PMHNP certification exam.

  • Older adults account for 20% of the total scored items (27 out of 135 items) on the AANP PMHNP certification exam.
  • First-line health promotion in older adults requires intervening at the lowest possible level of prevention.
  • Primary prevention stops health problems before they occur, such as ensuring adequate home illumination for a 76-year-old man with PTSD and OCD to prevent fall injuries.
  • Secondary prevention focuses on early detection through screening, such as screening a 76-year-old man for physical, emotional, or financial abuse.
  • Tertiary prevention minimizes negative outcomes in established illness, such as utilizing an Employee Assistance Program or adjusting medication regimens.
  • The selected review sources cover general exam architecture and prevention levels, but omit Fitzgerald Chapter 17 text and specific deprescribing rules.
• Rule of Titration: Start Low, Go Slow, But Get to GoalOlder Adult Domain Weight: Older adults (ages 65 and older) account for 20 percent (27 scored items) of the total AANPCB certification examination.

  • Older Adult Domain Weight: Older adults (ages 65 and older) account for 20 percent (27 scored items) of the total AANPCB certification examination.
  • Primary Prevention in Older Adults: Focuses on preventing health problems before they occur, such as ordering an annual influenza vaccine for a 66-year-old patient with schizophrenia or ensuring adequate home lighting for a 76-year-old to prevent falls.
  • Secondary Prevention in Older Adults: Focuses on early detection through screening, such as screening a 76-year-old man with PTSD and OCD for physical, emotional, or financial abuse.
  • Tertiary Prevention in Older Adults: Focuses on managing established disease and adjusting therapy to minimize negative disease-induced outcomes and prevent further organ damage, such as adjusting psychotropic medication in a 66-year-old with schizophrenia.
  • Lifespan Scope: Both ANCC and AANPCB exams integrate lifespan content randomly across items rather than dividing content into distinct age blocks.
• Primary Prevention in Geriatric CareDefinition: Preventing a health condition before it develops.

  • Definition: Preventing a health condition before it develops.
  • First-line Examples: Administering the influenza vaccine to older adults, counseling on safety, and ensuring home environmental safety such as proper lighting to prevent falls.
  • Primary prevention is the most cost-effective form of healthcare intervention.

  Safety. Primary prevention is the most cost-effective form of healthcare intervention.

• Secondary Prevention in Geriatric CareDefinition: Detecting disease in an early, asymptomatic, or preclinical stage to minimize impact.

  • Definition: Detecting disease in an early, asymptomatic, or preclinical stage to minimize impact.
  • First-line Examples: Performing screening tests, such as checking blood pressure, ordering lipid panels, or screening an older adult for physical, emotional, or financial elder abuse.
  • Do not confuse screening (secondary prevention) with treating or adjusting medication for an already established diagnosis (tertiary prevention).

  Board trap. Do not confuse screening (secondary prevention) with treating or adjusting medication for an already established diagnosis (tertiary prevention).

• Tertiary Prevention in Geriatric CareDefinition: Minimizing negative outcomes in patients with established disease.

  • Definition: Minimizing negative outcomes in patients with established disease.
  • First-line Examples: Adjusting psychotropic medication regimens, optimizing symptom control, and coordinating rehabilitation or employee assistance programs after acute stabilization.
  • Tertiary prevention can be viewed clinically as a failure of primary prevention, requiring ongoing adjustments to avoid target organ damage or functional decline.

  Safety. Tertiary prevention can be viewed clinically as a failure of primary prevention, requiring ongoing adjustments to avoid target organ damage or functional decline.

• A) Primary preventionB: Secondary prevention involves screening for early asymptomatic disease, not vaccination.

  • B: Secondary prevention involves screening for early asymptomatic disease, not vaccination.
  • C: Tertiary prevention involves managing an existing disease to prevent complications.
  • D: Quaternary prevention is not a standard board-tested level of health promotion.
• B) Secondary preventionA: Primary prevention stops an injury or illness before it happens, such as home lighting modifications.

  • A: Primary prevention stops an injury or illness before it happens, such as home lighting modifications.
  • C: Tertiary prevention manages known, established disease complications.
  • D: Harm reduction is a clinical strategy for substance use, not a standard level of prevention category.
• C) Tertiary preventionA: Primary prevention prevents disease onset.

  • A: Primary prevention prevents disease onset.
  • B: Secondary prevention identifies asymptomatic disease through screening.
  • D: Health promotion is a broad concept typically aligned with primary prevention rather than established disease management.
• Practice Question: Geriatric Depression Treatment SelectionSertraline and escitalopram are preferred SSRI choices for geriatric depression due to low anticholinergic activity and favorable drug interaction profiles.

  • Sertraline and escitalopram are preferred SSRI choices for geriatric depression due to low anticholinergic activity and favorable drug interaction profiles.
  • Paroxetine is listed on Beers criteria and should be avoided in older adults due to potent anticholinergic effects, sedation, and CYP2D6 inhibition.
  • Citalopram carries a maximum dose limit of 20 mg per day in patients over age 60 years due to dose-dependent QTc prolongation.
  • Assuming a normal serum creatinine indicates normal renal clearance in an older adult. Age-related loss of muscle mass masks renal decline, so always check eGFR before dosing.
  • Tricyclic antidepressants like amitriptyline are strongly avoided in older adults due to high anticholinergic burden, orthostatic hypotension, confusion, and fall risk.
  • Mirtazapine is an effective alternative for geriatric depression accompanied by severe insomnia or weight loss due to its antihistaminic appetite-stimulating and sedating effects at lower doses.

  Board trap. Assuming a normal serum creatinine indicates normal renal clearance in an older adult. Age-related loss of muscle mass masks renal decline, so always check eGFR before dosing.

  Safety. Paroxetine is listed on Beers criteria and should be avoided in older adults due to potent anticholinergic effects, sedation, and CYP2D6 inhibition.

• Sertraline and EscitalopramFast mental label: Preferred geriatric SSRIs.

  • Fast mental label: Preferred geriatric SSRIs.
  • Priority: Lowest risk of CYP450 drug interactions and minimal anticholinergic burden.
  • Boards are testing: Recognizing safe first-line prescribing in polypharmacy.
• ParoxetineFast mental label: High-risk geriatric SSRI.

  • Fast mental label: High-risk geriatric SSRI.
  • Priority: Strong anticholinergic and sedating properties.
  • Boards are testing: Identifying drugs on Beers criteria that cause cognitive impairment, constipation, and urinary retention.
• CitalopramFast mental label: Dosed-capped SSRI.

  • Fast mental label: Dosed-capped SSRI.
  • Priority: Cardiac safety and QTc prolongation monitoring.
  • Boards are testing: Knowing the 20 mg per day limit for patients older than 60 years.
• Amitriptyline and ImipramineFast mental label: High-hazard tricyclic antidepressants.

  • Fast mental label: High-hazard tricyclic antidepressants.
  • Priority: Severe anticholinergic toxicity, sedation, and cardiac conduction delays.
  • Boards are testing: Avoiding TCAs in older adults due to fall and arrhythmia risks.
• Antipsychotics: Black Box Warning and TD RiskAIMS monitoring schedule: Perform the Abnormal Involuntary Movement Scale (AIMS) at baseline before initiating any antipsychotic, and repeat the assessment every 3 to 6 months in older adults or high-risk individuals.

  • AIMS monitoring schedule: Perform the Abnormal Involuntary Movement Scale (AIMS) at baseline before initiating any antipsychotic, and repeat the assessment every 3 to 6 months in older adults or high-risk individuals.
  • First-line intervention for BPSD: Non-pharmacological interventions, including environmental modifications, behavioral redirection, and identifying underlying physical causes like pain or infection, are first-line for dementia-related agitation.
  • TD management protocol: If involuntary oro-facial-lingual or choreiform movements occur, discontinue or taper the antipsychotic if clinically safe, switch to a lower-risk SGA like quetiapine or clozapine, or consider VMAT2 inhibitors such as valbenazine or deutetrabenazine.
• FDA Black Box Warning and Mortality RiskClinical trial data demonstrate a 1.6 to 1.7 times increase in all-cause mortality among elderly patients with **dementia-related psychosis** treated with antipsychotics compared to placebo.

  • Clinical trial data demonstrate a 1.6 to 1.7 times increase in all-cause mortality among elderly patients with **dementia-related psychosis** treated with antipsychotics compared to placebo.
  • The predominant causes of death in these clinical trials were cardiovascular events, including heart failure and sudden cardiac death, as well as infectious complications, particularly pneumonia.
  • Furthermore, antipsychotic use in patients with Alzheimer's disease or vascular dementia increases the incidence of cerebrovascular adverse events, including transient ischemic attacks and stroke.
  • **Board trap**: Exam items frequently present an elderly resident with **dementia** who exhibits mild nighttime agitation, wandering, or uncooperative behavior during bathing, and ask for the **first** or **most appropriate** prescription.

  Board trap. Exam items frequently present an elderly resident with dementia who exhibits mild nighttime agitation, wandering, or uncooperative behavior during bathing, and ask for the first or most appropriate prescription. Test-takers often succumb to the trap of selecting an SGA like queti

  Safety. The FDA Black Box Warning applies universally across the entire antipsychotic class, encompassing both first-generation antipsychotics (such as haloperidol and fluphenazine) and second-generation antipsychotics (such as risperidone, olanzapine, quetiapine, aripiprazole, and zipra

• Tardive Dyskinesia Risk and AIMS AssessmentNon-pharmacological strategies remain the first-line standard of care for non-emergent behavioral distress in neurocognitive disorders. When non-pharmacological methods prove insufficient and severe psychotic distress or physical aggression creates an immediate safety hazard, sho

  • First-line**: Non-pharmacological strategies remain the **first-line** standard of care for non-emergent behavioral distress in neurocognitive disorders.
  • When non-pharmacological methods prove insufficient and severe psychotic distress or physical aggression creates an immediate safety hazard, short-term pharmacotherapy may be initiated using the lowest available starting dose.
  • **Tardive dyskinesia** manifests as involuntary, repetitive, choreoathetoid movements affecting the oro-facial-lingual muscles (tongue protrusion, lip smacking, puckering, grimacing) and choreiform movements of the extremities and trunk.
  • To monitor for TD effectively, the PMHNP must administer the **Abnormal Involuntary Movement Scale** (AIMS) prior to initiating any antipsychotic agent to establish a baseline.
• First-Generation Antipsychotics vs Second-Generation Antipsychotics in Older AdultsDo not confuse: Both FGAs and SGAs carry the identical FDA Black Box Warning for increased mortality in dementia-related psychosis, but their adverse effect profiles differ significantly.

  • Do not confuse: Both FGAs and SGAs carry the identical FDA Black Box Warning for increased mortality in dementia-related psychosis, but their adverse effect profiles differ significantly.
  • Think FGAs (e.g., Haloperidol) when: High-potency D2 receptor antagonism creates severe risk for acute dystonia, drug-induced parkinsonism, and tardive dyskinesia in older adults.
  • Think SGAs (e.g., Quetiapine, Risperidone) when: Serotonin 5-HT2A and lower D2 receptor affinity reduce EPS and TD risk, but increase the incidence of metabolic syndrome, orthostatic hypotension, sedation, and falls.
  • Priority difference: Neither class is indicated for routine dementia behavior, but if emergency chemical stabilization is required for acute physical danger, low-dose SGAs are preferred over FGAs to reduce motor toxicity.
  • Boards are testing: Recognition that selecting an SGA over an FGA does not eliminate the Black Box Warning for mortality in older adults with dementia.
  • Classic distractor: Choosing quetiapine under the mistaken belief that its lower EPS risk makes it FDA-approved for dementia-related agitation.
• Tardive Dyskinesia vs Drug-Induced ParkinsonismDo not confuse: Both conditions represent motor complications of antipsychotic D2 blockade, but their clinical presentations and pharmacological management are directly opposing.

  • Do not confuse: Both conditions represent motor complications of antipsychotic D2 blockade, but their clinical presentations and pharmacological management are directly opposing.
  • Think Tardive Dyskinesia when: Involuntary, hyperkinetic, choreoathetoid movements (lip smacking, tongue rolling, facial grimacing) appearing after prolonged antipsychotic exposure; symptoms worsen with anticholinergic administration.
  • Think Drug-Induced Parkinsonism when: Hypokinetic rigidity, bradykinesia, resting tremor, and a shuffling gait appearing within days to weeks of starting or escalating an antipsychotic; symptoms improve with anticholinergics or dose reduction.
  • Priority difference: Administering an anticholinergic like benztropine relieves parkinsonian rigidity but worsens or unmasks tardive dyskinesia.
  • Boards are testing: Distinguishing hyperkinetic involuntary movements (TD) from hypokinetic muscle stiffness (parkinsonism) prior to selecting an intervention.
  • Classic distractor: Ordering benztropine for an elderly patient displaying involuntary tongue protrusion and lip puckering.
• Benzodiazepines: Falls and the LOT ExceptionGeriatric Exam Weight: Older adults account for 20% of examination items (27 scored questions) on the AANPCB certification exam.

  • Geriatric Exam Weight: Older adults account for 20% of examination items (27 scored questions) on the AANPCB certification exam.
  • Primary Prevention: Interventions aimed at preventing a health problem or injury before it occurs, such as ensuring adequate home illumination for a 76-year-old patient to prevent falls.
  • Secondary Prevention: Early detection and screening of disease or harm in an asymptomatic state to minimize impact, such as screening a 76-year-old patient for physical, emotional, or financial abuse, or ordering a lipid profile to detect metabolic risk.
  • Tertiary Prevention: Managing established clinical disease to prevent complications, disability, or target organ damage, such as adjusting medication therapy or monitoring lithium levels in a patient with a known diagnosis.
  • Lowest Level Principle: The core primary healthcare principle is to intervene at the lowest level of prevention possible to achieve optimal patient outcomes.
  • A) Primary prevention
• SSRI Selection and Hyponatremia MonitoringThe AANPCB certification exam designates 20% of test questions (27 scored items) specifically to the older adult population.

  • The AANPCB certification exam designates 20% of test questions (27 scored items) specifically to the older adult population.
  • The ANCC examination evaluates psychiatric and physical health concepts across the entire lifespan from infant to frail elder.
  • Intervening at the lowest level of prevention possible is a core board principle.
  • Primary prevention stops disease before onset through health promotion, education, or injury reduction.
  • Secondary prevention identifies preclinical or asymptomatic illness through screening tools and routine lab checks.
  • Tertiary prevention manages established illness to reduce complications, adjust medication regimens, or minimize target organ damage.
• Primary Prevention in Older AdultsEnsuring adequate home illumination for a 76-year-old patient with PTSD is primary prevention because it prevents falls before an injury occurs.

  • Environmental risk reduction prevents acute physical trauma in vulnerable older adults.
  • Ensuring adequate home illumination for a 76-year-old patient with PTSD is primary prevention because it prevents falls before an injury occurs.
  • Immunizations: Administering the annual influenza vaccine to a 66-year-old patient with schizophrenia represents primary disease prevention.

  Safety. Environmental risk reduction prevents acute physical trauma in vulnerable older adults.

• Secondary Prevention in Older AdultsScreening a 76-year-old male for physical, emotional, or financial abuse is secondary prevention.

  • Confusing routine screening with treatment management. Screening tests always represent secondary prevention.
  • Screening a 76-year-old male for physical, emotional, or financial abuse is secondary prevention.
  • Lab checks: Obtaining a lipid panel or routine blood pressure check to catch asymptomatic metabolic or cardiovascular illness early is secondary prevention.

  Board trap. Confusing routine screening with treatment management. Screening tests always represent secondary prevention.

• Tertiary Prevention in Older AdultsAdjusting psychotropic medication therapy in a 66-year-old patient with schizophrenia to enhance symptom regulation represents tertiary prevention.

  • Adjusting psychotropic medication therapy in a 66-year-old patient with schizophrenia to enhance symptom regulation represents tertiary prevention.
  • Disease management: Accessing an Employee Assistance Program or modifying established treatment to prevent disease progression is tertiary prevention.
• High-Yield Bottom LineFirst-line SSRIs for geriatric depression are sertraline and escitalopram due to low CYP450 enzyme inhibition and minimal drug interaction risks.

  • First-line SSRIs for geriatric depression are sertraline and escitalopram due to low CYP450 enzyme inhibition and minimal drug interaction risks.
  • Citalopram is capped at a maximum dose of 20 mg daily in adults over age 60 due to the risk of dose-dependent QTc interval prolongation and Torsades de Pointes.
  • Mirtazapine is the preferred agent when geriatric depression is accompanied by severe insomnia and unintentional weight loss, acting via histamine H1 and serotonin receptor antagonism.
  • Duloxetine is the preferred SNRI when depression co-occurs with chronic neuropathic pain or musculoskeletal pain.
  • Bupropion is ideal for geriatric depression presenting with severe fatigue, apathy, or psychomotor slowing, but is strictly contraindicated in patients with seizure disorders or active eating disorders.
  • SSRIs and SNRIs carry a significant risk of causing hyponatremia secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion, particularly within the first 2 to 4 weeks of initiation in older adults taking thiazide diuretics.

  Board trap. TCAs such as amitriptyline and imipramine, as well as the SSRI paroxetine, should be avoided in older adults according to the Beers Criteria due to severe anticholinergic effects, sedation, orthostatic hypotension, and fall risk.

  Safety. SSRIs and SNRIs carry a significant risk of causing hyponatremia secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion, particularly within the first 2 to 4 weeks of initiation in older adults taking thiazide diuretics.

• First-Line SSRI and SNRI SelectionCitalopram is also effective, but carries a specific FDA warning in the geriatric population. Due to the risk of QTc interval prolongation and lethal ventricular arrhythmias, the maximum daily dose of citalopram for any patient older than 60 years is 20 mg daily.

  • Citalopram is also effective, but carries a specific FDA warning in the geriatric population. Due to the risk of QTc interval prolongation and lethal ventricular arrhythmias, the maximum daily dose of citalopram for any patient older than 60 years is 20 mg daily.
• Critical Safety Alerts and Monitoring ParametersSafety alert**: SSRI-induced hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone secretion occur at significantly higher rates in geriatric patients.

  • Safety alert**: SSRI-induced hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone secretion occur at significantly higher rates in geriatric patients.
  • **Board trap**: Do not mistake SSRI-induced hyponatremia in an older adult for worsening dementia or new-onset delirium.
  • A sudden presentation of lethargy, confusion, weakness, or gait instability shortly after initiating an antidepressant requires an immediate basic metabolic panel to evaluate serum sodium.
  • When initiating any recommended antidepressant in an older adult, adhere to the foundational geriatric principle: start low, go slow, but titrate to full therapeutic doses.

  Board trap. Do not mistake SSRI-induced hyponatremia in an older adult for worsening dementia or new-onset delirium. A sudden presentation of lethargy, confusion, weakness, or gait instability shortly after initiating an antidepressant requires an immediate basic metabolic panel to evaluate

  Safety. SSRI-induced hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone secretion occur at significantly higher rates in geriatric patients. Clinicians should obtain a baseline serum sodium level prior to starting an SSRI or SNRI and recheck serum sodium within 2 to 4 weeks

• CYP2D6 Inhibition: Fluoxetine and ParoxetineCYP2D6 Potent Inhibitors: Fluoxetine and paroxetine are potent inhibitors of the cytochrome P450 2D6 isoenzyme and should generally be avoided in older adults on multi-drug regimens.

  • CYP2D6 Potent Inhibitors: Fluoxetine and paroxetine are potent inhibitors of the cytochrome P450 2D6 isoenzyme and should generally be avoided in older adults on multi-drug regimens.
  • Cardiovascular Risk: Inhibiting CYP2D6 blocks the clearance of substrate beta-blockers like metoprolol, propranolol, and carvedilol, leading to toxic drug accumulation, severe bradycardia, heart block, hypotension, and falls.
  • Tricyclic Toxicity: Co-administering fluoxetine or paroxetine with tricyclic antidepressants such as nortriptyline or desipramine increases TCA blood concentrations, risking QTc prolongation, fatal cardiac arrhythmias, and seizures.
  • Analgesic Failure: CYP2D6 inhibition prevents the metabolic conversion of prodrugs like codeine and tramadol into their active analgesic metabolites, resulting in complete therapeutic failure for pain management.
  • Dosing Thresholds in Geriatrics: Age-related reduction in hepatic volume and blood flow decreases drug clearance; fluoxetine has a long active metabolite half-life of 1 to 2 weeks, extending interaction risks long after discontinuation.
  • First-Line Alternatives: In older adults requiring an SSRI, select agents with minimal CYP enzyme inhibition, specifically sertraline, escitalopram (maximum 10 mg daily in elderly), or citalopram (maximum 20 mg daily in elderly).
• Clinical Signposts for Board MasteryFor geriatric depression or anxiety, sertraline, escitalopram, or citalopram represent first-line SSRI choices because they possess minimal CYP450 enzyme inhibition profiles. Always observe elderly dosing caps: citalopram is capped at 20 mg daily and escitalopram is capped at 10

  • Safety Alert**: Always perform a comprehensive medication reconciliation before initiating **fluoxetine** or **paroxetine**.
  • Check for **CYP2D6** substrates, particularly cardiovascular medications and TCAs.
  • Due to the extended half-life of **fluoxetine** and its active metabolite **norfluoxetine** (7 to 15 days), **CYP2D6** inhibition persists for several weeks after stopping the medication.
  • - **Board Trap**: Board questions often present an older adult taking **metoprolol** who develops new-onset **bradycardia**, fatigue, and dizziness after starting a new antidepressant.

  Board trap. Board questions often present an older adult taking metoprolol who develops new-onset bradycardia, fatigue, and dizziness after starting a new antidepressant. The distractor choice will suggest a cardiology consult, pacemaker evaluation, or adding a stimulant. The correct action

  Safety. Always perform a comprehensive medication reconciliation before initiating fluoxetine or paroxetine. Check for CYP2D6 substrates, particularly cardiovascular medications and TCAs. Due to the extended half-life of fluoxetine and its active metabolite norfluoxetine (7 to 15 days),

• Comparing SSRI Isoenzyme Profiles in Older AdultsSertraline, Escitalopram, and Citalopram: Minimal to mild CYP2D6 and CYP3A4 inhibition. Low potential for pharmacokinetic drug interactions, making them the preferred first-line choices for older adults.

  • Sertraline, Escitalopram, and Citalopram: Minimal to mild CYP2D6 and CYP3A4 inhibition. Low potential for pharmacokinetic drug interactions, making them the preferred first-line choices for older adults.
• C) **ParoxetineA) Sertraline exhibits minimal CYP enzyme inhibition at lower doses and is a preferred first-line antidepressant in older adults with cardiovascular comorbidities.

  • A) Sertraline exhibits minimal CYP enzyme inhibition at lower doses and is a preferred first-line antidepressant in older adults with cardiovascular comorbidities.
  • B) Escitalopram has negligible CYP enzyme inhibition and does not significantly alter metoprolol metabolism.
  • D) Vilazodone does not potently inhibit CYP2D6 and does not carry the same high risk of beta-blocker interaction.
• B) **Fluoxetine** inhibits **CYP2D6**, preventing conversion of **codeine** to morphineCodeine is a prodrug that requires bioactivation into morphine via the CYP2D6 pathway to exert its analgesic effect. Fluoxetine is a potent CYP2D6 inhibitor. Inhibiting this enzyme blocks the metabolic conversion, leaving the patient with inadequate pain relief.

  • Codeine is a prodrug that requires bioactivation into morphine via the CYP2D6 pathway to exert its analgesic effect. Fluoxetine is a potent CYP2D6 inhibitor. Inhibiting this enzyme blocks the metabolic conversion, leaving the patient with inadequate pain relief.
  • A) Fluoxetine does not alter renal clearance mechanisms for opioid medications.
  • C) Fluoxetine acts on serotonin reuptake transporters, not mu-opioid receptors.
  • D) Fluoxetine is an inhibitor of CYP2D6, not a CYP3A4 inducer.
• Anticholinergic Toxicity and Cognitive ImpairmentPrescribing Cascade Definition: A prescribing cascade occurs when an adverse drug reaction caused by one medication is misdiagnosed as a new medical condition, leading to the prescription of a second medication to treat the side effect.

  • Prescribing Cascade Definition: A prescribing cascade occurs when an adverse drug reaction caused by one medication is misdiagnosed as a new medical condition, leading to the prescription of a second medication to treat the side effect.
  • Anticholinergic Cognitive Burden: Medications with high anticholinergic activity impair central M1 muscarinic receptors, causing acute delirium, memory loss, confusion, and accelerated cognitive decline in older adults.
  • The Anticholinergic-Cholinesterase Inhibitor Cascade: Prescribing a cholinesterase inhibitor like donepezil to treat cognitive loss caused by diphenhydramine or amitriptyline is a classic board-tested prescribing cascade that opposes therapeutic mechanisms.
  • The Urinary Incontinence Cascade: Cholinesterase inhibitors increase acetylcholine levels and frequently cause bladder hyperreactivity and urinary incontinence, which is often misdiagnosed and inappropriately treated with oxybutynin, worsening central cognitive impairment.
  • Deprescribing Protocol: The priority management for medication-induced cognitive decline is step-wise deprescribing, tapering the offending anticholinergic drug, and re-evaluating baseline cognition after clearance.
• Prescribing Cascades in Geriatric PracticeWhen an older adult presents with new cognitive symptoms, urinary retention, or behavioral changes, the first-line intervention is always a comprehensive medication reconciliation to identify and deprescribe anticholinergic agents before adding any new medication or primary psych

  • 1. Patient takes donepezil for mild cognitive impairment or Alzheimer disease.
  • 2. Elevated peripheral acetylcholine causes detrusor muscle contraction, resulting in new-onset urinary incontinence.
  • 3. Provider misinterprets incontinence as age-related detrusor instability and prescribes oxybutynin.
  • 4. Oxybutynin crosses the blood-brain barrier, antagonizes central cholinergic receptors, neutralizes the therapeutic effect of donepezil, and triggers acute delirium or rapid cognitive decline.

  Board trap. Test writers frequently present an older adult taking an over-the-counter sleep aid containing diphenhydramine or a tricyclic antidepressant like amitriptyline who develops progressive memory loss. The trap option is to diagnose early Alzheimer disease and initiate donepezil or g

• Central Anticholinergic ToxicityThink: Central nervous system cholinergic blockade in the brain.

  • Think: Central nervous system cholinergic blockade in the brain.
  • Priority: Immediate risk for acute delirium, confusion, memory failure, and falls.
  • Key Clues: Disorientation, hallucinations, impaired recall, executive dysfunction, lethargy.
  • Boards are Testing: Recognizing that central cognitive impairment can occur even when peripheral signs are mild or absent.
• Peripheral Anticholinergic Side EffectsThink: Peripheral muscarinic receptor blockade in body tissues.

  • Think: Peripheral muscarinic receptor blockade in body tissues.
  • Priority: Physical discomfort, bowel obstruction, and urinary tract complications.
  • Key Clues: Dry mouth, blurred vision, constipation, urinary retention, sinus tachycardia, anhidrosis.
  • Boards are Testing: Differentiating physical anticholinergic side effects from primary medical conditions like benign prostatic hyperplasia or constipation.
• Prescribing CascadeThink: Adverse drug reaction misdiagnosed as a new clinical condition.

  • Think: Adverse drug reaction misdiagnosed as a new clinical condition.
  • Priority: Harm reduction through medication reduction and elimination.
  • Key Clues: Onset of new physical or cognitive symptoms shortly after starting or titrating a medication.
  • Boards are Testing: Identifying the root cause medication and deprescribing rather than adding a second drug to treat the side effect.
• Primary Neurocognitive Disorder (Dementia)Think: Progressive, neurodegenerative decline in cognitive domains over months to years.

  • Think: Progressive, neurodegenerative decline in cognitive domains over months to years.
  • Priority: Accurate longitudinal assessment, safety planning, and evidence-based disease management.
  • Key Clues: Gradual onset, insidious progression, absence of acute medication triggers or fluctuating delirium.
  • Boards are Testing: Ruling out reversible medication-induced causes before establishing a primary dementia diagnosis.
• Metabolic and Cardiac Monitoring ProtocolIntervene at the lowest applicable level of prevention to maximize cost-effectiveness and optimize clinical outcomes.

  • Primary prevention prevents health problems before they occur, such as administering an influenza vaccine to a 66-year-old with schizophrenia or recommending physical activity to a 25-year-old with major depressive disorder.
  • Secondary prevention detects disease in an early, preclinical, or asymptomatic state to minimize health impact, such as ordering a baseline lipid profile for a patient with major depressive disorder and a family history of type 2 diabetes.
  • Tertiary prevention manages established illness to prevent target organ damage, reduce disability, and avoid complications, such as adjusting a lithium dosage for bipolar disorder or utilizing an Employee Assistance Program.
  • When monitoring metabolic risk factors in patients taking psychotropics, ordering routine screening labs like a lipid profile or blood pressure check is classified as secondary prevention.
  • Selecting primary prevention or secondary prevention when a patient accesses post-hospitalization rehabilitation or workplace support; accessing an Employee Assistance Program after a manic episode is tertiary prevention because the condition is already established.
  • Intervene at the lowest applicable level of prevention to maximize cost-effectiveness and optimize clinical outcomes.

  Board trap. Selecting primary prevention or secondary prevention when a patient accesses post-hospitalization rehabilitation or workplace support; accessing an Employee Assistance Program after a manic episode is tertiary prevention because the condition is already established.

  Safety. When monitoring metabolic risk factors in patients taking psychotropics, ordering routine screening labs like a lipid profile or blood pressure check is classified as secondary prevention.

• Practice Question: Drug-Induced Dementia PresentationMedication reconciliation is the mandatory initial assessment for any older adult presenting with new or rapidly accelerating cognitive decline.

  • Medication reconciliation is the mandatory initial assessment for any older adult presenting with new or rapidly accelerating cognitive decline.
  • First-generation antihistamines, tricyclic antidepressants, and oral bladder antimuscarinics possess potent central anticholinergic activity that induces reversible cognitive impairment and delirium in older adults.
  • Prescribing cascades occur when an adverse drug reaction is misdiagnosed as a new medical condition, leading to additional inappropriate prescriptions.
  • Co-prescribing donepezil with oxybutynin represents a major prescribing cascade because the muscarinic blocker directly neutralizes the central acetylcholinesterase inhibitor.
  • The American Geriatrics Society Beers Criteria strongly advises avoiding high-anticholinergic drugs in older adults due to elevated risks of cognitive decline, urinary retention, constipation, and falls.
  • Age-related declines in renal clearance cause drug accumulation even when serum creatinine remains within normal reference ranges due to decreased muscle mass.
• Drug-Induced Cognitive Impairment in Older AdultsConduct a comprehensive medication review and calculate cumulative anticholinergic burden using validated tools or Beers Criteria guidance.

  • Core Pathology: Central M1 muscarinic receptor blockade impairs cholinergic neurotransmission in the hippocampus and cortex, producing symptoms that mimic or worsen major neurocognitive disorder.
  • Key Offending Medications: Diphenhydramine, hydroxyzine, amitriptyline, doxepin, oxybutynin, tolterodine, cyclobenzaprine, and alprazolam.
  • Conduct a comprehensive medication review and calculate cumulative anticholinergic burden using validated tools or Beers Criteria guidance.
  • High anticholinergic burden in older adults significantly increases 1-year mortality, fall risk, acute delirium, and emergency room visits.
  • Assuming recent memory loss in an 80-year-old patient represents irreversible Alzheimer disease without first auditing recent medication changes or OTC sleep aid use.

  Board trap. Assuming recent memory loss in an 80-year-old patient represents irreversible Alzheimer disease without first auditing recent medication changes or OTC sleep aid use.

  Safety. High anticholinergic burden in older adults significantly increases 1-year mortality, fall risk, acute delirium, and emergency room visits.

• Prescribing Cascades and Cholinesterase NeutralizationDeprescribe the non-essential anticholinergic agent or switch to a uro-selective beta-3 agonist like mirabegron that lacks central anticholinergic activity.

  • Mechanism: A patient prescribed donepezil develops urge incontinence as a cholinergic side effect; the clinician prescribes oxybutynin to treat incontinence, which crosses the blood-brain barrier and blocks the cholinergic boost provided by donepezil.
  • Clinical Result: Cognitive scores drop, prompting the clinician to increase the donepezil dose or add memantine, escalating the cascade.
  • Deprescribe the non-essential anticholinergic agent or switch to a uro-selective beta-3 agonist like mirabegron that lacks central anticholinergic activity.
• Drug-Induced Cognitive ImpairmentThink: Subacute onset of confusion and memory loss temporally linked to new prescription additions, dose increases, or over-the-counter anticholinergic sleep aids.

  • Think: Subacute onset of confusion and memory loss temporally linked to new prescription additions, dose increases, or over-the-counter anticholinergic sleep aids.
  • Priority: Discontinue offending drugs and reassess cognitive baseline over 4 to 8 weeks.
  • Boards are testing: Recognition of reversible drug toxicity and application of deprescribing principles.
• Primary Neurocognitive DisorderThink: Insidious, slowly progressive cognitive decline occurring over months to years without acute temporal relation to new drug starts.

  • Think: Insidious, slowly progressive cognitive decline occurring over months to years without acute temporal relation to new drug starts.
  • Priority: Establish baseline cognitive testing, rule out metabolic and infectious causes, and initiate evidence-based cholinesterase inhibitors if appropriate.
  • Boards are testing: Standard diagnostic criteria and longitudinal management of primary dementias.
• C) Order a brain MRI to evaluate for acute cerebrovascular eventsWhy the Other Choices Are Wrong:

  • Why the Other Choices Are Wrong:
  • A: Increasing donepezil escalates drug exposure without resolving the ongoing pharmacologic antagonism caused by oxybutynin and diphenhydramine.
  • C: Ordering a brain MRI is premature before addressing clear, reversible medication-induced causes of cognitive decline.
  • D: Adding memantine escalates the prescribing cascade by adding another psychotropic drug without removing the underlying offending agents.
  • Test-Taking Pearl: When an older adult presents with sudden or subacute cognitive decline, always audit the medication list for anticholinergic and sedative drugs before adding new psychiatric medications or ordering complex imaging.